

DETAILED ACTION
EXAMINER'S AMENDMENT

An examiner's amendment to the record appears below. Should the changes and/or additions be unacceptable to applicant, an amendment may be filed as provided by 37 CFR 1.312. To ensure consideration of such an amendment, it **MUST** be submitted no later than the payment of the issue fee.

Authorization for this examiner's amendment was given in a telephone interview with Mary Wilson on March 9, 2010.

In the claims:

6. (Currently Amended) A process for producing an isolated polynucleotide sequence encoding a modified polypeptide comprising: i) modifying a polynucleotide sequence that comprises a DNA sequence encoding a polypeptide comprising an aspartic protease amino acid sequence to encode an extra polypeptide N-X-T glycosylation site in the aspartic protease amino acid sequence; and ii) isolating the polynucleotide sequence resulting from step (i) which isolated polynucleotide sequence encodes the modified polypeptide, wherein the modified polypeptide comprises at least one -N-X-T- site introduced at position 291-293 (with reference to SEQ ID NO: 1), according to the chymosin numbering.

7. (Previously Presented) The process for producing an isolated polynucleotide sequence of claim 6, wherein the modified polypeptide is modified by substituting S₂₉₃ with T (with reference to SEQ ID NO: 1), creating the at least one N-X-T glycosylation site.

20. (Currently Amended) An isolated polypeptide exhibiting aspartic protease activity comprising a N-X-T glycosylation site wherein the polypeptide comprises at least one -N X-T- site introduced at position 291-293 (with reference to SEQ ID NO: 1), according to the chymosin numbering.

21. (Original) The isolated polypeptide of claim 20, wherein the polypeptide comprises T₂₉₃ (with reference to SEQ ID NO: 1), creating a N-X-T glycosylation site.

The following is an examiner's statement of reasons for allowance: The Board reversed the Examiner.

Any comments considered necessary by applicant must be submitted no later than the payment of the issue fee and, to avoid processing delays, should preferably accompany the issue fee. Such submissions should be clearly labeled "Comments on Statement of Reasons for Allowance."

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Michele K. Joike whose telephone number is (571)272-5915. The examiner can normally be reached on M-F, 10:00-6:30.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Christopher Low can be reached on (571)272-0951. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Michele K. Joike/
Primary Examiner, Art Unit 1636

Michele K. Joike
Primary Examiner
Art Unit 1636